NCT07762443 A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata
| NCT ID | NCT07762443 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Jiangsu vcare pharmaceutical technology co., LTD |
| Condition | Alopecia Areata |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2026-09-22 |
| Primary Completion | 2027-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2026-09-22 with a primary completion date of 2027-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a multicenter, open-label, non-randomized, dose-finding Phase I study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with severe alopecia areata (AA).
Eligibility Criteria
Inclusion Criteria: * The subject fully understands this study and is able to comply with the relevant trial procedures. The subject and their legal guardian voluntarily sign the informed consent form (ICF). * Age 12 to 18 years inclusive (including 12 years old, excluding 18 years old) at the time of signing the ICF, both genders, with body weight ≥ 40 kg. * Subjects must meet the diagnostic criteria for alopecia areata (AA) at both screening and baseline visits. Exclusion Criteria: * Women who are pregnant or breastfeeding, or subjects who plan to become pregnant or breastfeed during the study period. * Subjects with a current diagnosis of acute diffuse alopecia areata (AA). * Subjects with a current diagnosis of other types of alopecia that may interfere with the evaluation of AA, including but not limited to traction alopecia, cicatricial alopecia, telogen effluvium, androgenetic alopecia, syphilitic alopecia, anagen effluvium, folliculotropic mycosis fungoides, or alopecia caused by thyroid disease, etc. * Subjects with other scalp diseases that may affect the assessment of AA, such as scalp psoriasis, dermatitis, tinea capitis, etc.
Contact & Investigator
Jianzhong Zhang
PRINCIPAL INVESTIGATOR
The Peking University People's Hospital, Beijing, Beijng
Frequently Asked Questions
Who can join the NCT07762443 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 18 Years, studying Alopecia Areata. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07762443 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07762443 currently recruiting?
Yes, NCT07762443 is actively recruiting participants. Contact the research team at lai_xiaojuan@vcarepharmatech.com for enrollment information.
Where is the NCT07762443 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07762443 clinical trial?
NCT07762443 is sponsored by Jiangsu vcare pharmaceutical technology co., LTD. The principal investigator is Jianzhong Zhang at The Peking University People's Hospital, Beijing, Beijng. The trial plans to enroll 24 participants.